A phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
Bewersdorf J, Verstovsek S, Derkach A, Masarova L, Pemmaraju N, Stein E, Mauro M, Rampal R, Bose P. A phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Journal Of Clinical Oncology 2023, 41: tps7086-tps7086. DOI: 10.1200/jco.2023.41.16_suppl.tps7086.Peer-Reviewed Original ResearchCDK4/6 inhibitorsSymptom scoresPhase I dose-escalation trialMedian overall survivalMD Anderson Cancer CenterDose-escalation designDuration of responseMaximum tolerated doseSafety of ruxolitinibSpleen volume reductionBiomarkers of responseHigh-risk diseasePhase I studyTreated with increasing dosesDose of ruxolitinibOral Janus kinaseLeft costal marginJanus kinase inhibitorsCDK4/6 inhibitor abemaciclibIncreased expression of CDC25AMechanism-based therapiesMeasures of efficacyFDA-approved CDK4/6 inhibitorsAge-matched controlsJanus kinase